DelveInsight’s, “Narcolepsy – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Narcolepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Narcolepsy Understanding
Narcolepsy: Overview
Narcolepsy is a disorder that disrupts sleep-wake processes. Its primary symptom is excessive daytime sleepiness (EDS), which occurs because the brain is unable to properly regulate wakefulness and sleep1. The symptoms of narcolepsy can have notable effects during both daytime and night time. Narcolepsy is often caused by a lack of the brain chemical hypocretin (also known as orexin), which regulates wakefulness. Methods of diagnosing narcolepsy and determining its severity include: sleep history, sleep records, polysomnography. There is no cure for narcolepsy, but medications and lifestyle modifications can help to manage the symptoms.

"Narcolepsy - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Narcolepsy pipeline landscape is provided which includes the disease overview and Narcolepsy treatment guidelines. The assessment part of the report embraces, in depth Narcolepsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Narcolepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
● The companies and academics are working to assess challenges and seek opportunities that could influence Narcolepsy R&D. The therapies under development are focused on novel approaches to treat/improve Narcolepsy.

Narcolepsy Emerging Drugs Chapters
This segment of the Narcolepsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Narcolepsy Emerging Drugs
● Sodium Oxybate (FT218): Avadel Pharmaceuticals
FT218 is an investigational, once-nightly formulation of sodium oxybate using a proprietary Micropump technology for extended-release oral suspension in the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients suffering from narcolepsy. Once-nightly FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy.

● Samelisant: Suven Life Sciences
Samelisant (SUVN-G3031) is a potent and selective histamine H3 receptor (H3R) inverse agonist with good brain penetration and oral bioavailability. Samelisant is in phase II cinical trials for the treatment of narcolepsy.
Further product details are provided in the report……..

Narcolepsy: Therapeutic Assessment
This segment of the report provides insights about the different Narcolepsy drugs segregated based on following parameters that define the scope of the report, such as:
● Major Players in Narcolepsy
There are approx. 5+ key companies which are developing the therapies for Narcolepsy. The companies which have their Narcolepsy drug candidates in the most advanced stage, i.e. phase III include, Avadel Pharmaceuticals.
● Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration
Narcolepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Subcutaneous
• Intravenous
• Intramuscular

● Molecule Type
Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
● Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Narcolepsy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Narcolepsy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Narcolepsy drugs.

Narcolepsy Report Insights
• Narcolepsy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Narcolepsy Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Narcolepsy drugs?
• How many Narcolepsy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Narcolepsy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Narcolepsy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Narcolepsy and their status?
• What are the key designations that have been granted to the emerging drugs?